Xalkori (crizotinib) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Pfizer Canada ULC. Xalkori (crizotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070448.PDF. Revised April 2023. Accessed June 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
XALKORI (crizotinib) is indicated for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). 1
XALKORI (crizotinib) is indicated for use in patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Crizotinib
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Crizotinib